

Series-30

PHARMACOVIGILANCE UNIT, KMCHHSR

DRUG SAFETY ALERT

MARCH– 2025

Indian Pharmacopoeia Commission (IPC) after the preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database reveals that the following suspected drug is associated with the ADR as given below.

S.NO	SUSPECTED DRUG	INDICATIONS	ADVERSE DRUG REACTION
1	Metronidazole	Amoebiasis, urogenital trichomoniasis & giardiasis.	Acute Generalised Exanthematous Pustulosis (AGEP)
2	Luliconazole	For the treatment of cutaneous mycosis viz. Tinea pedis, Tinea corporis and Tinea cruris.	Chloasma/Melasma
3	Dalteparin	Symptomatic Venous Thromboembolism (VTE) proximal Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) to reduce the recurrence of VTE in patients with cancer.	Muscle spasms
4	Gliclazide	Diabetes without or with obesity in adults	Erythema multiforme
5	Tramadol	For the treatment of severe acute and chronic pain, diagnostic measures and surgical pain.	Fixed Drug Eruption

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If, such reaction is encountered, please report to the Pharmacovigilance unit, KMCHHSR via **Email (pharmacovigilance@kmchihsr.edu.in)** /**Landline No ([04226806808](tel:04226806808))**.

Click on the below link to find the list of Monthly Drug Safety Alerts from Mar 2016 to Till date: https://www.ipc.gov.in/images/List_of_Drug_Safety_Alerts_issued_by_PvPI_IPC_till_date.pdf